Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Elliquis

- PMLiVE

Pfizer warns against price-cutting after NICE backs Bosulif

Cancer drug is the first to be re-appraised form the CDF

Bristol-Myers Squibb (BMS) building

Bristol-Myers Squibb acquires Cormorant for $520m

Deal with Swedish firm will boost BMS' oncology pipeline

- PMLiVE

Pfizer set to snap up Bind’s assets for $20m

Biotech approves 'stalking horse' bid from the pharma giant

Bristol-Myers Squibb (BMS) building

NICE ‘no’ for Opdivo in kidney cancer

BMS oncology drug knocked-back in draft guidance

Bristol-Myers Squibb (BMS) building

BMS to explore new options for its immuno-oncology drug Opdivo

Partners with PsiOxis to research its use with enadenotucirev

- PMLiVE

Merck & Co signs cancer vaccines research deal for Keytruda

Will work on range of personalised vaccines to complement its blockbuster

- PMLiVE

inVentiv Health wins Pfizer account

Will be tasked with managing the pharma firm’s global clinical services

China drug medicine pharma prices

Pfizer earmarks $350m for first Asian biotech facility

US pharma giant looks to tap into China’s pharmaceuticals market

- PMLiVE

BMS appoints Murdo Gordon as chief commercial officer

He also becomes executive vice president

- PMLiVE

Ariad files early marketing application for brigatinib

Second-line lung cancer therapy could be on the market by early 2017

- PMLiVE

Trial backs Keytruda use first-line in lung cancer

Suggests Merck & Co’s drug is more effective than chemotherapy for NSCLC patients

Shire Basingstoke

Shire receives FDA nod for self-infusion of Glassia

The company has also struck a deal with Pfizer to expand its GI portfolio

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links